Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
105
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Anlotinib Combined with Cranial Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Retrospectively, Control Study

Zelai He1 The First Affiliated Hospital of Bengbu Medical College & Tumor Hospital Affiliated to Bengbu Medical College, Bengbu, 233004, People’s Republic of China
,
Jia Liu1 The First Affiliated Hospital of Bengbu Medical College & Tumor Hospital Affiliated to Bengbu Medical College, Bengbu, 233004, People’s Republic of China
,
Yuwei Ma1 The First Affiliated Hospital of Bengbu Medical College & Tumor Hospital Affiliated to Bengbu Medical College, Bengbu, 233004, People’s Republic of China
,
Hao Jiang1 The First Affiliated Hospital of Bengbu Medical College & Tumor Hospital Affiliated to Bengbu Medical College, Bengbu, 233004, People’s Republic of China
,
Zhen Cui1 The First Affiliated Hospital of Bengbu Medical College & Tumor Hospital Affiliated to Bengbu Medical College, Bengbu, 233004, People’s Republic of China
,
Guowen Wang1 The First Affiliated Hospital of Bengbu Medical College & Tumor Hospital Affiliated to Bengbu Medical College, Bengbu, 233004, People’s Republic of China
,
Yufeng Wu2 Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, 450008, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-0510-0388
ORCID Icon,
Jiuzhou Liu3 The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, 471003, People’s Republic of China
,
Xixi Cai4 Department of Radiation Oncology, The Second Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, People’s Republic of China
,
Jing Qian1 The First Affiliated Hospital of Bengbu Medical College & Tumor Hospital Affiliated to Bengbu Medical College, Bengbu, 233004, People’s Republic of China
,
Jingwen Huang1 The First Affiliated Hospital of Bengbu Medical College & Tumor Hospital Affiliated to Bengbu Medical College, Bengbu, 233004, People’s Republic of China
,
Huijun Zhang5 Department of Cardiothoracic Surgery, Huashan Hospital of Fudan University, Shanghai, 200040, People’s Republic of ChinaCorrespondence[email protected] [email protected]
&
Hongwei Li1 The First Affiliated Hospital of Bengbu Medical College & Tumor Hospital Affiliated to Bengbu Medical College, Bengbu, 233004, People’s Republic of China
 show all
Pages 6101-6111 | Published online: 04 Aug 2021

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
  • Zhang H, Wang A, Tan Y, et al. NCBP1 promotes the development of lung adenocarcinoma through up-regulation of CUL4B. J Cell Mol Med. 2019;23(10):6965–6977. doi:10.1111/jcmm.1458131448526
  • He Z, Shi Z, Sun W, et al. Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer. Tumour Biol. 2016;37(6):7809–7821. doi:10.1007/s13277-015-4634-126695149
  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.2166033538338
  • Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019;12(1):47. doi:10.1186/s13045-019-0736-331046803
  • Yang ZR, Liu MN, Yu JH, et al. Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy. Transl Lung Cancer Res. 2020;9(5):2059–2073. doi:10.21037/tlcr-20-89633209626
  • Alcibar OL, Nadal E, Romero Palomar I, Navarro-Martin A. Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer. Transl Lung Cancer Res. 2021;10(1):529–538. doi:10.21037/tlcr-2020-nsclc-0433569334
  • Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. doi:10.1186/s13045-018-0664-730231931
  • Si X, Zhang L, Wang H, et al. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center Phase III trial of anlotinib in patients with advanced non-small cell lung cancer. Lung Cancer. 2018;122:32–37. doi:10.1016/j.lungcan.2018.05.01330032842
  • Si X, Zhang L, Wang H, et al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: experiences in ALTER-0303. Thorac Cancer. 2019;10(3):551–556. doi:10.1111/1759-7714.1297730666799
  • Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.303930098152
  • Jiang S, Liang H, Liu Z, et al. The impact of anlotinib on brain metastases of non-small cell lung cancer: post hoc analysis of a phase III randomized control trial (ALTER0303). Oncologist. 2020;25(5):870–874. doi:10.1634/theoncologist.2019-0838
  • Brun L, Dupic G, Chassin V, et al. Hypofractionated stereotactic radiotherapy for large brain metastases: optimizing the dosimetric parameters. Cancer Radiother. 2021;25(1):1–7. doi:10.1016/j.canrad.2020.04.01133257109
  • Kahrom A, Grimley R, Jeffree RL. A case of delayed cyst formation post brain AVM stereotactic radiosurgery for arteriovenous malformation: case report. J Clin Neurosci. 2021;87:17–19. doi:10.1016/j.jocn.2021.01.05133863526
  • Lancia A, Merizzoli E, Filippi AR. The 8(th) UICC/AJCC TNM edition for non-small cell lung cancer staging: getting off to a flying start? Ann Transl Med. 2019;7(Suppl6):S205. doi:10.21037/atm.2019.07.0231656784
  • Duan Y, Qian J, Chen K, Zhang Z. Necessity of adjuvant postoperative radiotherapy for diffuse pigmented villonodular synovitis of the knee: a case report and literature review. Medicine. 2018;97(3):e9637. doi:10.1097/md.000000000000963729504995
  • He Z, Zhang H, Cui Z, et al. A case of chemorefractory metastatic type AB thymoma sensitive to helical tomotherapy. Ann Transl Med. 2019;7(12):274. doi:10.21037/atm.2019.05.3431355241
  • Han B, Li K, Zhao Y, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118(5):654–661. doi:10.1038/bjc.2017.47829438373
  • Li Y, Liu J, Li HX, et al. Radiomics signature facilitates organ-saving strategy in patients with esophageal squamous cell cancer receiving neoadjuvant chemoradiotherapy. Front Oncol. 2020;10:615167. doi:10.3389/fonc.2020.61516733680935
  • Gao XH, Zheng J, Ma L, et al. Mitigation of acute radiation-induced brain injury in a mouse model using anlotinib. Ann Palliat Med. 2021;10(1):312–322. doi:10.21037/apm-20-228433545766
  • Wang Y, Liang D, Chen J, et al. Targeted therapy with anlotinib for a patient with an oncogenic FGFR3-TACC3 fusion and recurrent glioblastoma. Oncologist. 2021;26(3):173–177. doi:10.1002/onco.1353032949176

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.